MARKET

TRIL

TRIL

TRILLIUM THERAPE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.670
-0.160
-5.65%
After Hours: 2.600 -0.07 -2.62% 19:58 01/17 EST
OPEN
2.800
PREV CLOSE
2.830
HIGH
2.960
LOW
2.510
VOLUME
3.04M
TURNOVER
--
52 WEEK HIGH
3.900
52 WEEK LOW
0.2405
MARKET CAP
74.86M
P/E (TTM)
-1.8746
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TRIL and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

TRIL News

  • Trillium Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
  • GlobeNewswire.3d ago
  • Trillium adds to TTI-621-stoked rally, up 22%
  • seekingalpha.01/10 20:07
  • SRNE, SEEL among premarket gainers
  • Seeking Alpha - Article.01/10 14:10
  • The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx
  • Benzinga.01/10 12:13

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About TRIL

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.
More

Webull offers Trillium Therapeutics Inc (TRIL) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.